Should you buy, sell or hold Cipla, Fortis Healthcare, Bharti Airtel, BPCL, ONGC shares today?

Brokerages are upbeat on Cipla despite the pharma company receiving eight observations from US drug regulator FDA for its Pithampur facility in Madhya Pradesh. They are bullish on Rekha Jhunjhunwala-owned Fortis Healthcare citing the company's good growth outlook, and divided on telecom stocks, such as Bharti Airtel and Indus Towers. 

Here's what top brokerages make of some of the key stocks in focus today:

Cipla shares

JPMorgan and Macquarie are upbeat on Cipla. According to the brokerage, the Pitampura unit is one of the company’s key manufacturing facilities besides Goa and the Invagen plant in the US.

Macquarie points out that Cipla manufactures respiratory products like Proventil Brovana and Pulmicort at the Pithampur plant.

Samvardhana Motherson shares

Jefferies maintains a ‘hold’ rating on Samvardhana Motherson with a target price of Rs 70 per share, as the company’s subsidiary acquires a 100 per cent stake in Germany's SAS Autosystemtechnik, a global provider of cockpit module assembly and logistics services to auto original equipment manufacturers (OEMs).

According to the brokerage, the acquisition will add 10-15 per cent to Motherson’s revenue and EBITDA. 

Telecom

Goldman Sachs maintains ‘buy’ on BPCL and ONGC. It has a ‘reduce’ rating each on the stock with target prices of Rs 295 and Rs 120 per share.